Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Alpha and Omega Semiconductor (AOSM) Q3 2026 Earnings Call - Advanced Computing Momentum Offsets Consumer Softness
Alpha and Omega Semiconductor delivered fiscal Q3 2026 revenue of $163.8 million, slightly above guidance, driven by strong demand in advanced computing (AI servers, graphics) that more than offset se...
- Q3 2026 revenue of $163.8 million slightly exceeded guidance, up 0.9% sequentially and down 0.5% year-over-year, with advanced computing (AI, servers, graphics) providing the primary growth driver.
- Advanced computing revenue surged over 40% year-over-year and now accounts for 25% of the computing segment, with strong traction in medium-voltage MOSFETs for hot-swap and intermediate bus converter applications.
- Management views the December and March quarters as the bottom for revenue and gross margin, signaling a constructive outlook for the second half of fiscal 2026.
- +10 more takeaways
Brilliant Earth Q1 2026 Earnings Call - Fine Jewelry Diversification Drives Margin Expansion and Brand Resilience
Brilliant Earth delivered a disciplined start to 2026 with net sales of $99.5 million, up 6% year-over-year, driven by a 3% increase in total orders and rising average selling prices across the assort...
- Net sales grew 6% year-over-year to $99.5 million, hitting the high end of guidance.
- Total orders increased 3% year-over-year, with repeat orders outpacing new customer growth.
- Fine jewelry bookings surged 33% year-over-year, now comprising 17% of total bookings.
- +7 more takeaways
Revolution Medicines Q1 2026 Earnings Call - Daraxonrasib Delivers Unprecedented Survival in Pancreatic Cancer, Fueling $2B Capital Raise
Revolution Medicines reported a pivotal quarter anchored by the top-line readout of RASolute 302, where daraxonrasib monotherapy demonstrated a 60% reduction in the risk of death and median overall su...
- Daraxonrasib monotherapy met primary and secondary endpoints in RASolute 302, showing a 60% reduction in risk of death and median overall survival exceeding 12 months in previously treated metastatic pancreatic cancer.
- The company executed a historic $2 billion dual-tranche capital raise, securing $2.1 billion in net proceeds to fund global development and commercialization efforts.
- FDA issued a safe-to-proceed letter for an expanded access protocol, allowing daraxonrasib distribution to eligible patients prior to formal regulatory approval.
- +7 more takeaways
Airgain Q1 2026 Earnings Call - Pipeline Expansion and Margin Pressure Define a Transition Quarter
Airgain’s first quarter of 2026 was a study in controlled transition. Management shifted the narrative from pure product sales to platform-driven, system-level connectivity, with Airgain Connect and L...
- Airgain Connect pipeline expanded roughly 40 percent to over 55 tier 1 and tier 2 opportunities, with a strategic shift toward non-first responder enterprise and utility markets.
- Acquisition of HPUE MegaFi 2 assets from Nextivity broadens the vehicle gateway portfolio, allowing Airgain to serve both fully integrated and standalone router needs.
- Lighthouse moved from network validation to commercial traction, partnering with a tier 1 U.S. Mobile Network Operator for live enterprise trials targeting late 2026.
- +7 more takeaways
Verra Mobility Q1 2026 Earnings Call - Government Solutions Drives Momentum Despite NYC Pricing Headwinds
Verra Mobility reported a solid first quarter with revenue of $224 million in line with expectations and adjusted EBITDA beating internal targets. The Government Solutions segment was the clear stando...
- Total revenue of $224 million aligned with internal expectations, while adjusted EBITDA of $86 million beat targets on better-than-anticipated New York City camera installations and reduced bad debt expense.
- Government Solutions bookings surged with $13 million in new awards in Q1, bringing trailing twelve-month bookings to approximately $71 million and highlighting sustained municipal demand for automated traffic enforcement.
- New York City contract pricing changes are creating near-term margin headwinds, with segment profit margins declining year-over-year, though faster-than-expected March installations helped offset some of the impact.
- +9 more takeaways
Hallador Energy Q1 2026 Earnings Call - $1.1B Capacity Deal Locks In 14-Year Revenue Visibility
Hallador Energy delivered a transformative milestone in its Q1 2026 earnings call, securing a 12-year, $1.1 billion capacity agreement that anchors forward revenue through 2040 at twice its historical...
- Hallador Energy secured a pivotal 12-year capacity agreement with a utility subsidiary, locking in over $1 billion in contracted revenue from 2028 through 2040 at pricing levels more than double its historical rates.
- The new agreement, combined with a March 2026 three-year capacity deal, places Hallador in a substantially sold-forward position on accredited capacity for approximately 14 consecutive years, providing unprecedented revenue visibility.
- Management explicitly differentiated between capacity and energy markets, noting that capacity is the current bottleneck for large load development while energy demand follows a multi-year lag as data centers and industrial projects come online.
- +7 more takeaways
Energy Recovery Inc. Q1 2026 Earnings Call - CEO Retirement, Middle East Guidance Withdrawn, New PX Q650 Launches
Energy Recovery reported a quarter defined by strategic transitions and geopolitical friction. CEO David Moon announced his retirement, while interim CFO Aidan Ryan stepped in after Mike Mancini’s dep...
- CEO David Moon announced his retirement, with a search for his successor underway. Interim CFO Aidan Ryan took over after Mike Mancini resigned.
- Launched the PX Q650 in March, securing its first commercial order and actively designing it into large desalination plants.
- Withdrew 2026 financial guidance for both desalination and wastewater due to uncertainty from the Middle East conflict.
- +9 more takeaways
Pattern Q1 2026 Earnings Call - Record NRR of 127% Drives Raised Full-Year Outlook
Pattern delivered a record start to 2026 with Q1 revenue surging 43% year-over-year to $774 million and adjusted EBITDA climbing 59% to $54 million. The company raised its full-year guidance, citing a...
- Q1 revenue grew 43% year-over-year to $774 million, driven by broad-based strength across existing brand partners, new marketplaces, and international expansion.
- Adjusted EBITDA reached $54 million, up 59% year-over-year, reflecting operating leverage despite increased R&D investments.
- Net revenue retention (NRR) hit a record 127%, up from 115% in the prior year, indicating strong expansion within the existing brand portfolio.
- +7 more takeaways
Warner Bros. Discovery Q1 2026 Earnings Call - Streaming Hits 140M Subscribers and Turns $2B Loss into Profit Ahead of Paramount Deal
Warner Bros. Discovery reported a strong Q1 2026, driven by streaming momentum and a successful content slate. HBO Max surpassed 140 million global subscribers, exceeding guidance, and the company tur...
- HBO Max surpassed 140 million global subscribers in Q1 2026, exceeding guidance, with management forecasting over 150 million by year-end.
- Streaming profitability has turned a corner, with the division generating $1.4 billion in profit last year after a $2 billion loss, signaling strong operating leverage.
- Warner Bros. Studios won 11 Oscars, including Best Picture for One Battle After Another, marking the studio’s most successful awards night in 103 years.
- +7 more takeaways
Vir Biotechnology Q1 2026 Earnings Call - Astellas Deal Closes as HDV Data Outpaces Competitors
Vir Biotechnology closed its $1.7B global partnership with Astellas for its T-cell engager VIR-5500, marking a transition from deal announcement to execution. The company received a $75M upfront equit...
- Vir Biotechnology closed its $1.7 billion global collaboration with Astellas for VIR-5500 on April 15, 2026, transitioning from deal announcement to active co-development and co-commercialization.
- The company received a $75 million upfront equity payment from Astellas and will receive an additional $240 million upfront payment within 30 days, significantly bolstering its balance sheet.
- Vir Biotechnology's cash runway is extended into the second half of 2028, supported by the Astellas deal proceeds and a $172.5 million follow-on equity offering closed in February 2026.
- +7 more takeaways